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OBJECTIVE—Insulin-mediated glucose uptake is highly sensi-
tive to the levels of the facilitative GLUT protein GLUT4.
Transcription of the GLUT4 gene is repressed in states of insulin
deﬁciency and insulin resistance and can be induced by states of
enhanced energy output, such as exercise. The cellular signals
that regulate GLUT4 transcription are not well understood. We
hypothesized that changes in energy substrate ﬂux regulate
GLUT4 transcription.
RESEARCH DESIGN AND METHODS—To test this hypothe-
sis, we used transgenic mice in which expression of the chlor-
amphenicol acetyltransferase (CAT) gene is driven by a
functional 895-bp fragment of the human GLUT4 promoter,
thereby acting as a reporter for transcriptional activity. Mice
were treated with a single dose of etomoxir, which inhibits the
transport of long-chain fatty acids into mitochondria and in-
creases basal, but not insulin-mediated, glucose ﬂux. GLUT4 and
transgenic CAT mRNA were measured.
RESULTS—Etomoxir treatment signiﬁcantly reduced CAT and
GLUT4 mRNA transcription in adipose tissue, but did not change
transcription in heart and skeletal muscle. Downregulation of
GLUT4 transcription was cell autonomous, since etomoxir treat-
ment of 3T3-L1 adipocytes resulted in a similar downregulation
of GLUT4 mRNA. GLUT4 transcriptional downregulation re-
quired the putative liver X receptor (LXR) binding site in the
human GLUT4 gene promoter in adipose tissue and 3T3-L1
adipocytes. Treatment of 3T3-L1 adipocytes with the LXR ago-
nist, TO901317, partially restored GLUT4 expression in eto-
moxir-treated cells.
CONCLUSIONS—Our data suggest that long-chain fatty acid
import into mitochondria in adipose tissue may produce ligands
that regulate expression of metabolic genes. Diabetes 59:
800–807, 2010
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LUT4 is the major insulin-responsive GLUT
responsible for insulin-dependent glucose dis-
posal. Insulin-mediated glucose homeostasis is
exquisitely sensitive to the level of GLUT4
protein. Mice that express exogenous GLUT4 gene in the
major GLUT4-expressing tissues, or in skeletal muscle or
adipose tissue alone, displayed enhanced insulin sensitiv-
ity and peripheral glucose utilization (1–4), whereas ge-
netic ablation of one or both alleles of the GLUT4 gene
result in insulin-resistant glucose disposal (5,6).
Expression of GLUT4 mRNA is subject to tissue-spe-
ciﬁc, hormonal, and/or metabolic regulation. GLUT4
mRNA expression is largely restricted to brown adipose,
white adipose, skeletal muscle, and cardiac muscle tis-
sues. Changes in GLUT4 gene expression are observed in
pathophysiological states of altered glucose homeostasis.
In general, GLUT4 mRNA expression is reduced in states
of relative insulin deﬁciency such as streptozotocin-in-
duced diabetes and chronic fasting (rev. in 7,8). Interest-
ingly, the regulated steady-state levels of GLUT4 mRNA
differ in various GLUT4-expressing tissues. For example,
streptozotocin-dependent changes in GLUT4 mRNA ex-
pression occur much more rapidly in adipose tissue than
skeletal muscle (9). Chronic fasting markedly reduces
GLUT4 mRNA levels in adipose tissue, but has little or no
effect on GLUT4 mRNA in skeletal muscle (10). Changes
in steady-state levels of GLUT4 mRNA most likely reﬂect
changes in the rate of mRNA synthesis (gene transcrip-
tion) as opposed to changes in mRNA half-life, as
evidenced by nuclear run-on assays showing that tran-
scription is decreased in both adipose tissue and skeletal
muscle in streptozotocin-induced diabetic animals (11,12),
while the rate of the GLUT4 gene transcription in skeletal
muscle of fasted animals is increased (12).
Regulation of GLUT4 gene expression within a narrow
range (two to threefold) has a signiﬁcant effect on whole
body glucose homeostasis, suggesting that a ﬁne control of
GLUT4 levels is important for adaptation to extreme
physiologic states such as prolonged fasting or to patho-
logic states such as chronic over nutrition. Because this
gene is under complex metabolic control, the molecular
basis for regulation of GLUT4 gene expression in altered
physiologic states has been difﬁcult to solve.
We hypothesize that changes in substrate ﬂux may
importantly contribute to the regulation of GLUT4 expres-
sion. These adaptive changes may emanate directly from
speciﬁc substrate utilization or may result from hormonal
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In this article, transgenic mice carrying the chloram-
phenicol acetyltransferase (CAT) gene under the control
of 895 bp of human GLUT4 promoter (hGLUT4-CAT) were
treated with etomoxir, an irreversible inhibitor of carnitine
palmitoyl transferase (CPT)-1. This treatment acutely in-
hibits mitochondrial long-chain fatty acid (LCFA) import
and oxidation, increases glucose oxidation in tissues that
normally oxidize fatty acids, and lowers circulating levels
of glucose (13–15). Etomoxir treatment caused decreased
GLUT4 transcription in adipose tissue but not in the heart
or hindquarter skeletal muscle. The effect on GLUT4
expression in adipose tissue was recapitulated in 3T3-L1
adipocytes and was mediated in part through a liver X
receptor element (LXRE) site in the GLUT4 promoter. Our
data support the hypothesis that GLUT4 expression is
regulated by cell-autonomous tissue-speciﬁc metabolic
signals.
RESEARCH DESIGN AND METHODS
Animals. Mice carrying a randomly integrated transgenic construct of the
CAT gene driven by 895 bp of the human GLUT4 promoter DNA (895-hGLUT4-
CAT) were obtained as previously described (16). A loss of function mutation
in the putative LXRE site of the human GLUT4 promoter was engineered into
the 895-HG4-CAT fragment and renamed -LXR-CAT. The mutation was
identical to that reported by Dalen et al. (17), changing human GLUT4 LXRE
(shown in bold) from GGGTTACTTTGGGGCA to GCCTTACTTTGCCGCA.
Mice were generated by the transgenic facility at the Oklahoma Medical
Research Foundation. Two independent founder lines were obtained and used
for experiments.
Mice carrying a conditional knockout of the insulin receptor gene in
cardiac tissue (CIRKO) were generated by crossing transgenic mice carrying
a ﬂoxed insulin receptor allele (IR
lox/lox) with transgenic mice expressing cre
recombinase driven by the -myosin heavy-chain promoter (18). A cross of
CIRKO mice and the 895-HG4-CAT mice was carried out to generate a novel
transgenic line (CIRKO-HG4-CAT). The new experimental mice have the
genotype 895-HG4-CAT-(Cre-IR
lox/lox), and control littermates have the
genotype 895-HG4-CAT-(IR
lox/lox). All mice were kept on a 12-h light/dark
cycle in a temperature/humidity-controlled room and had access to free water
and standard food. All procedures using animals were approved by the
Institutional Animal Care and Use Committee at the University of Oklahoma
Health Sciences Center.
RNA extraction, quantitative real-time PCR, and RNase protection
assay. Mice were killed by CO2 asphyxiation. Tissues were excised and
snap-frozen and RNA was extracted as previously described (16). RNA was
quantiﬁed by ultraviolet absorbance at 260, 280, and 320 nm.
CAT, mGLUT4, and actin mRNA was quantiﬁed by quantitative real-time
(qrt)-PCR. The relative copy number of actin was used for normalization.
The mRNA levels were calculated using a standard curve of an ultraviolet
quantiﬁed qrt-PCR sample, speciﬁc to the primer set. Primer sequences
were as follows: CAT, 5-TCCGGCAGTTTCTACACATA-3 (forward), 5-
TGGCTGAGACGAAAAACATA-3 (reverse); mGLUT4, 5-AAAAGTGCCTGA
AACCAGAG-3 (forward), 5-TCACCTCCTGCTCTAAAAGG-3 (reverse); and
actin, 5-CCTCACTGACTACCTGATGA-3 (forward), 5-AGCTCATAGCTCTT
CTCCAG-3 (reverse). All qrt-PCRs were run using an iCycler iQ real-time PCR
detection system thermal cycler (Bio-Rad). CIRKO-HG4-CAT sample mRNA
was quantiﬁed by RNase protection assay as previously described (19).
Metabolic measurements. Blood was collected via tail bleed between 9 and
10 AM from fed animals. Blood glucose was measured using the True-Track
smart system glucose meter (Walgreens). Tissue triacylglycerol content was
measured using a triglyceride determination kit (T0100; Sigma-Aldrich).
Measurement of cAMP levels in adipose tissue was made using a radioimmu-
noassay kit (Sigma-Aldrich).
Mitochondrial extraction and analysis. Liver and muscle tissues were
snap-frozen in liquid nitrogen. Tissues were homogenized in 20 volumes of
ice-cold mitochondrial homogenization buffer (10 mmol/l MOPS, pH 7.4, 0.1%
BSA). Carnitine palmitoyl transferase activity was assayed in the post-nuclear
500-g supernatant by diluting (1:10 for muscle preparations and 1:40 for liver
preparations) in homogenization buffer containing 0.1 mmol/l dithio-nitroben-
zoic acid, 0.1 mmol/l palmitoyl CoA, and 10 mmol/l carnitine to a ﬁnal volume
of 1 ml. Change in absorbance at 412 nm wavelength was monitored at 10-s
intervals for 1.5 min to estimate the rate of cleavage of palmitoyl CoA.
Luciferase assays. 3T3-L1 adipocytes were differentiated and electroporated
as previously described (20). Luciferase assays were performed as previously
described with plasmids encoding LXR-, myocyte enhancer factor (MEF)-2A,
and GLUT4 enhancer factor (GEF) 24 h after transfection (21).
Chromatin immunoprecipitation. Three 10-cm plates of 3T3-L1 adipocytes
(9 days post-differentiation) were either untreated or treated for 24 h with 25
nmol/l etomoxir, washed in ice-cold 1  PBS, and ﬁxed at room temperature
with 1% formaldehyde in Ham’s F-12 starvation media for 10 min. Fixation was
stopped by incubation for 5 min with stop-ﬁx solution (125 mmol/l glycine, 11
mmol/l Na2HPO4, 1.98 mmol/l KH2PO4, 2.97 mmol/l KCl, and 165 mmol/l NaCl).
Cells were scraped into 1  PBS containing 0.5 mmol/l PMSF, pelleted at 1,000
g at 4°C, and then lysed in buffer (5 mmol/l PIPES, pH 8.0, 85 mmol/l KCl, 0.5%
NP-40, and protease inhibitors). Crude nuclear pellets were pelleted at 1,000
g at 4°C. The nuclear fraction was resuspended in nuclear lysis buffer (1 
PBS, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, protease inhibitor
cocktail). Chromatin was sheared by sonication on ice 10 times (20 s on, 30 s
off), and insoluble debris was pelleted at 10,000 g at 4°C. An aliquot
representing 10% was analyzed as “input.” Supernatant was transferred to a
fresh tube and incubated overnight at 4°C with 3 g of the antibody (anti-LXR
[sc-13068X] or normal rabbit IgG, Santa Cruz Biotechnology). Magnetic
protein G beads were added the next day and incubated for 4 h, at 4°C. Beads
were washed twice with nuclear lysis buffer and four times with wash buffer
(100 mmol/l Tris [pH 8.0], 500 mmol/l LiCl, 1% NP-40, 1% deoxycholate). The
beads were resuspended in elution buffer (1% SDS, 0.1 mol/l NaHCO3) and
incubated at 67°C for2ht oreverse cross-linking. Beads were pelleted at
12,000 g, and the supernatant was incubated overnight at 67°C to further
reverse cross-linking. Supernatant was then cleared by spinning at 10,000g and
puriﬁed using phenol/chloroform extraction and subjected to PCR. GLUT4-
speciﬁc primers were used to expand the region between domain I and the
MEF2 binding domain: GLUT4 forward, 5-GGAGGGGATGGGCCAGTA;
GLUT4 reverse, 5-GCCCCGAAGTAACCCGGA. The PCR products were sep-
arated using 3% agarose gel electrophoresis.
Statistical analysis. Mean and SE of the mean is reported. Differences were
analyzed using a two-tailed Student’s t test.
RESULTS
Insulin resistance and obesity is associated with incom-
plete fatty acid oxidation (22,23). To explore the conse-
quences of decreased fatty acid oxidation on GLUT4
transcription, we acutely inhibited CPT-1 and thus LCFA
entry into the mitochondria. Two-month-old male mice
were given one intraperitoneal injection of etomoxir (50
mg/kg body wt). Etomoxir inhibits CPT-1 through an
irreversible modiﬁcation of the active site of CPT-A
(24,25). To ensure that etomoxir inhibited CPT-1 activity,
we performed a CPT assay in crude mitochondrial prepa-
rations from hindquarter skeletal muscle, heart, and liver.
CPT-1 activity was inhibited in all tissues tested (Fig. 1A).
Fed glucose levels were decreased nearly 50% (P  0.05)
after treatment with etomoxir (Fig. 1B). Wet weight of
perigonadal adipose tissue and subscapular brown adi-
pose tissue were unchanged by etomoxir treatment, sug-
gesting that lipids were not mobilized from these tissues
(Fig. 1C). Intracellular triacylglycerides were estimated by
measuring glycerol content of a total lipid extract after
treatment with lipase enzyme. Overnight treatment with
etomoxir signiﬁcantly increased intracellular triacylglycer-
ides in liver tissue and heart (P  0.05) (Fig. 1D). By
contrast, triacylglycerol content of hindquarter skeletal
muscle was signiﬁcantly decreased in etomoxir-treated
mice (Fig. 1D).
We then tested GLUT4 promoter function under eto-
moxir treatment using a line of transgenic animals that
carry the CAT reporter gene expressed under the control
of an 895-bp fragment of the human GLUT4 promoter
(895-HG4-CAT) (Fig. 2A). We have previously demon-
strated that this fragment of the human GLUT4 promoter
is sufﬁcient to direct tissue-speciﬁc and regulated expres-
sion of the CAT gene in a manner that is identical to
endogenous mouse GLUT4 (16). To this end, CAT and
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adipose tissue and white adipose tissue, hindquarter skeletal
muscle, and heart tissue. The effects of etomoxir treatment
on CAT gene expression and endogenous GLUT4 gene
expression were highly tissue speciﬁc. CAT mRNA and
GLUT4 mRNA levels in brown adipose tissue and white
adipose tissue were decreased (P  0.05) in both male and
female mice (Fig. 2B). In contrast, CAT mRNA and GLUT4
mRNA in hindquarter skeletal muscle and heart were
unaffected by etomoxir treatment (Fig. 2B).
Because blood glucose levels were decreased after
etomoxir treatment, we reasoned that insulin levels would
also be decreased, and this could lead to downregulation
of GLUT4 gene transcription. Using conditional tissue-
speciﬁc knockouts of the insulin receptor, several studies
have shown that GLUT4 protein is not decreased in
adipose tissue, skeletal muscle, or cardiac tissue
(18,26,27). To check whether the transcriptional regula-
tion of the GLUT4 gene was changed by the absence of
insulin receptor signaling, we made use of the cardiac-
speciﬁc receptor knockout of the insulin receptor
(CIRKO) model. CIRKO mice were crossed with trans-
genic mice carrying the 895-HG4-CAT genotype. The
CIRKO-HG4-CAT mice were evaluated for their level of
CAT and endogenous GLUT4 mRNA expression using the
RNAse protection assay. CAT and GLUT4 mRNA expres-
sion appear to be unchanged with the loss of an intact
insulin receptor (Fig. 3).
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FIG. 2. Effects of etomoxir on CAT and GLUT4 expression. The 2- to
3-month-old male transgenic mice were injected intraperitoneally with
50 mg/kg body wt of etomoxir. A: This depicts the schematic drawing of
the 895-HG4-CAT construct used to construct this line of transgenic
mice. B: After 18 h, total RNA was isolated from white adipose tissue
(WAT), brown adipose tissue (BAT), hindquarter muscle (HQT), and
heart (HRT) tissues. qrt-PCR was used to determine mRNA levels of
CAT, GLUT4, and actin. CAT and GLUT4 expression was normalized to
actin expression levels. Data were analyzed using a two-tailed Stu-
dent’s t test. *Signiﬁcant difference between control (CON) and
etomoxir-treated (ETO) (P < 0.05).
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into mitochondria, we reasoned that a signal to the GLUT4
promoter might be mediated through the putative LXRE
on the human GLUT4 promoter. LXR signaling promotes
fat storage; therefore, we reasoned that changes in fat
oxidation could be sensed through this signaling pathway
(28). To test this hypothesis, we generated a line of
transgenic mice carrying a loss of function mutation in the
LXRE site in the context of the 895-HG4-CAT transgenic
construct. This new mutant construct (-LXR-CAT) was
used to generate two founder lines of mice. Both founder
lines expressed transgenic mRNA in the GLUT4-express-
ing tissues, but restricted expression in tissues that do not
normally express GLUT4 (data not shown). From this, we
conclude that the LXRE site was not required for a
tissue-speciﬁc expression pattern of the transgene. To
determine the role of LXRE in mediating the downregula-
tion of GLUT4 mRNA under etomoxir treatment, we
calculated the ratio of CAT mRNA to GLUT4 mRNA in
white and brown adipose treatment in both lines of
transgenic mice (Fig. 4). In animals carrying 895-HG4-
CAT, the ratio of CAT to GLUT4 remained the same
because CAT and GLUT4 mRNA were downregulated to
the same extent with etomoxir. In contrast, the ratio of
CAT mRNA to GLUT4 mRNA doubled with etomoxir
treatment in adipose tissues from animals carrying the
-LXR-CAT construct (Fig. 4).
To determine if etomoxir downregulates GLUT4
through changes in the hormones or other systemic fac-
tors other than insulin, we treated 3T3-L1 adipocytes with
etomoxir overnight and measured GLUT4 mRNA (Fig.
5A). Similar to adipose tissue in vivo, etomoxir treatment
downregulates GLUT4 mRNA in 3T3-L1 adipocytes about
fourfold. To determine if the etomoxir-induced changes
were due to inhibition of long-chain fatty acid import, we
sought to restore GLUT4 mRNA by providing palmitoyl-L-
carnitine. Etomoxir-treated cells were further treated
without or with 1 mmol/l palmitoyl-L-carnitine to bypass
carnitine-palmitoyl-transferase activity. This treatment re-
stored GLUT4 mRNA to 75% of control levels (Fig. 5B),
conﬁrming that the major effect of etomoxir was due to
inhibited formation of acyl carnitines.
In transgenic animals, the signal to downregulate
GLUT4 mRNA was mediated, in part, through the LXRE of
the GLUT4 promoter. To further elucidate LXRE function,
we expressed either a luciferase promoter driven by the
human GLUT4 promoter (895-HG4-LUC) or the con-
struct carrying the loss-of-function mutation in the LXRE
(-LXR-HG4-Luc) in 3T3-L1 adipocytes. The constructs
were transactivated by overexpression of MEF2A and GEF
to boost the signal. Mutation of the LXRE site resulted in
a highly reproducible and statistically signiﬁcant decrease
in reporter expression (Fig. 6A). When cells were treated
with etomoxir, expression of 895-HG4-Luc was de-
creased 50% (Fig. 6A). Expression of -LXR-HG4-Luc
decreased no further upon etomoxir treatment, suggesting
that effects of etomoxir treatment are mediated, in part,
through LXR signaling. To determine if the LXRE element
was bound by LXR protein, we performed chromatin
immunoprecipitation using an antibody raised against
LXR-. LXR- speciﬁcally bound the GLUT4 promoter in
control 3T3-L1 adipocytes (Fig. 6B); however, LXR- bind-
ing was reduced in etomoxir treatment. Quantiﬁcation of
three independent experiments revealed that etomoxir
reduced binding by 84% compared with control cells (see
Fig. 7C for quantiﬁcation).
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coupled with long-chain acyl carnitine formation, we
sought to determine the signaling pathway to activate to
restore GLUT4 mRNA. Because the LXRE element was
required for downregulation, we treated cells with the
LXR agonist TO901317 (Calbiochem). Treatment with
TO901317 partially restored GLUT4 mRNA to a level that
was not statistically lower than control (Fig. 7A). To
determine if TO901317 treatment inﬂuenced LXR binding
to the GLUT4 promoter, we performed chromatin immu-
noprecipitation using control and etomoxir cell extracts
without and with treatment with TO901317. As before,
etomoxir treatment reduced LXR- association with the
GLUT4 promoter (Fig. 7B and C). Treatment of both
control and etomoxir-treated cells with TO901317 signiﬁ-
cantly enhanced LXR binding to the GLUT4 promoter (Fig.
7B and C). This suggests that occupancy of the LXRE
domain with LXR ligand is required for full activation of
GLUT4 gene expression, but that LXRE ligand occupancy
is not rate-setting for GLUT4 transcription.
DISCUSSION
We have demonstrated that acute inhibition of LCFA
import into mitochondria results in a tissue-restricted
downregulation of GLUT4 gene transcription in adipose
tissue, but not in skeletal muscle or heart tissue (Fig. 2).
Recently, several laboratories have provided evidence
supporting a model for dysregulation of lipid metabolism
as a cause of insulin resistance (23,29,30). These papers
invoke several mechanisms including increased levels of
ceramide (30), increased levels of the signaling and bio-
synthetic intermediate diacylglycerol (29), and reduced
capacity for mitochondrial oxidation of fatty acids (23) as
the cause of insulin resistance. Because the level of
GLUT4 expression may play a role in chronic insulin
resistance, it seems likely that changes in lipid metabolism
could regulate GLUT4 transcription and contribute to
downregulation of GLUT4 mRNA. We reasoned that inhi-
bition of mitochondrial LCFA might also play a role in
generating a metabolic signal leading to regulation of
GLUT4 transcription. We observed that the acute inhibi-
tion of mitochondrial LCFA inhibited GLUT4 transcription
in white and brown adipose tissue, but did not alter
transcription in skeletal muscle or heart (Fig. 2). This
suggests that inhibition of LCFA import, per se, does not
directly inhibit GLUT4 transcription, but rather the fate of
the imported LCFA in a given tissue may generate a signal
to the GLUT4 promoter. Therefore, the effect of etomoxir
on adipose tissue reveals a unique function for mitochon-
drial LCFA import in this tissue.
In our model, intracellular triacylglycerol accumulated
in liver and heart tissue, but not skeletal muscle (Fig. 1).
This was unexpected, since previous studies showed that
etomoxir treatment in rats led to increased triacylglycerol
in skeletal muscle (31). The different ﬁndings in the
C57BL/6 mice used in this study compared with rats
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L-carnitine (PLC) in HEPES-buffered saline, pH 7.4, was added to
etomoxir-treated cells. Total RNA was isolated and qrt-PCR was used
to determine mRNA levels of GLUT4 and actin. Data were analyzed
using a two-tailed Student’s t test. *Signiﬁcantly different from control
(CON) (P < 0.05).
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FIG. 6. Role of the GLUT4 promoter LXRE in GLUT4 gene transcrip-
tion. A: 3T3–L1 adipocytes (day 5 post-differentiation) were trans-
fected with GLUT4 reporter/luciferase (ﬁreﬂy luciferase) reporter
plasmids, GLUT4 enhancer factor (GEF) and MEF2 ( indicates
inclusion in transfection), and pRLTKluc (Renilla luciferase, for trans-
fection efﬁciency). Immediately after transfection, the cells were
treated without or with 25 nmol/l etomoxir (ETO). After 24 h, cells
were harvested and luciferase assays performed in cell lysates. Data
were analyzed using a Student’s t test. Statistical signiﬁcance between
groups is indicated by lines. B: Chromatin immunoprecipitation using
nuclear extracts from adipocytes (8 days post-differentiation) was
performed using an anti–LXR- antibody and nonimmune IgG. Quanti-
ﬁcation of this representative chromatin immunoprecipitation is pre-
sented in Fig. 7C. CON, control.
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metabolism. For instance, the C57BL/6 mice may have
increased secretion of free fatty acids and triacylglycerol
from skeletal muscle or decreased uptake of free fatty
acids from adipose tissue and liver. Nonetheless, the
accumulation of triacylglycerol in heart tissue did not
correlate with a downregulation of GLUT4 transcription,
suggesting that these events are not directly linked. This is
somewhat surprising to us, since increased triacylglycerol
levels in hearts of mice with a cardiac-speciﬁc overexpres-
sion of lipoprotein lipase correlated with decreased
GLUT4 mRNA levels (32). That study might reﬂect a
chronic adaptation to continued high levels of triacylglyc-
erol in those transgenic mice.
In humans and rodents, diabetes and obesity lead to
downregulation of GLUT4 gene transcription in adipose
tissue (19,33–35). The signaling pathways that are respon-
sible remain elusive. GLUT4 expression in adipose tissue
is also downregulated in response to prolonged fasting.
Downregulation of adipose GLUT4 in diabetes and fasting
are consistent with the notion that GLUT4 transcription is
regulated by decreased insulin signaling, increased coun-
terregulatory hormone secretion, or the concomitant
changes in substrate ﬂux that accompany both insulin
resistance and fasting (34,36). For example, during insulin
resistance and fasting, insulin signaling is reduced, insulin-
mediated glucose ﬂux is low, and circulating fatty acids
are high. Insulin resistance and fasting have similar effects
on adipose tissue metabolism, including increased lipoly-
sis with release of fatty acids and glycerol that is used for
hepatic gluconeogenesis (37). On the other hand, insulin
resistance states and fasting have different effects on
substrate utilization in skeletal muscle. Fatty acid oxida-
tion is inhibited in insulin resistance, while it is quite active
in fasting (22,23,38). In muscles of obese and type 2
diabetics, glucose oxidation in the fasted state in much
higher than lean controls, and there is little or no differ-
ence in fatty acid oxidation between the fed and fasted
states (38).
We have now used a metabolic paradigm that incorpo-
rates aspects of both enhanced glucose utilization of
plasma glucose levels and decreased lipid utilization to
examine the effects on GLUT4 expression. Etomoxir-
treatment inhibited 	-oxidation by inhibiting CPT-1 activ-
ity and lowered blood glucose levels (Fig. 1). Previous
studies in rats have shown that etomoxir treatment lowers
insulin levels, but does not necessarily lead to lipolysis,
since the fat mass was reported to be increased and
circulating free fatty acids not elevated (31). In the current
study, we found that neither adipose tissue wet weight
(Fig. 1C) nor cAMP levels (data not shown) were altered
under etomoxir treatment. Nevertheless, the GLUT4 tran-
scription levels in both brown and white adipose tissue
were reduced under etomoxir treatment consistent with a
shift away from glucose utilization in adipose tissue,
thereby increasing its availability for other organs.
Although we have not shown it directly, it is unlikely
that the downregulation of GLUT4 transcription in adi-
pose tissue is due to low levels of signaling through the
insulin receptor. First, the adipose-speciﬁc knockout of
the insulin receptor does not alter GLUT4 protein expres-
sion (18). Second, we demonstrated that GLUT4 transcrip-
tion in heart is not altered by cardiac-speciﬁc knockout of
the insulin receptor (Fig. 3). While we did not ﬁnd that
etomoxir led to changes in cardiac GLUT4 gene expres-
sion, the ﬁndings that insulin receptor signaling is not
required for GLUT4 transcription in the cardiac tissue is
evidence that other signals likely regulate the GLUT4
promoter.
GLUT4 transcription is differentially regulated in adi-
pose tissue compared with muscle tissue. The differences
in transcription likely reﬂect differences in the physiologic
and metabolic roles that each of these tissues play. In
adipose tissue, GLUT4 may be playing a role in energy
sensing, whereas in muscle tissue, GLUT4 may play a more
important role in fuel selection. This is supported by
evidence that GLUT4 knockout mice oxidize fatty acids at
a signiﬁcantly higher rate than wild-type mice (39,40).
Moreover, skeletal muscle and adipose tissue respond
differently to activation of AMP-activated protein kinase
(AMPK). In skeletal muscle, AMPK activation leads to
increased glucose uptake and fatty acid oxidation presum-
ably to increase ATP levels, while in adipose tissue, AMPK
activation inhibits these processes, presumably allowing
free fatty acids to be released from adipocytes for use in
other tissues (41,42). In part, the effects of AMPK on
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FIG. 7. Treatment with LXR agonist recovers GLUT4 mRNA expression
in etomoxir-treated cells. A: 3T3–L1 adipocytes (day 6–8 post-differ-
entiation) were treated with 25 nmol/l etomoxir without or with 0.1
mol/l TO901317. After 18 h, total RNA was isolated for quantiﬁcation
of GLUT4 and actin mRNA. B: Chromatin immunoprecipitation (ChIP)
using nuclear extracts from adipocytes (8 days post-differentiation)
was performed using an anti–LXR- antibody and nonimmune IgG.
Cells were treated without and with 25 nmol/l etomoxir (ETO) and/or
0.1 mol/l TO901317 as described in A. C: Quantiﬁcation of three
independent ChIP experiments using qrt-PCR. IgG background is
subtracted from the LXR antibody ChIPs. Data were analyzed using
two-tailed Student’s t test. Bars with different lowercase letters are
signiﬁcantly different from one another (P < 0.05). CON, control.
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increased GLUT4 gene transcription in muscle (43,44).
GLUT4 transcription is regulated by metabolic changes
that are associated with insulin resistance, but might not
be directly regulated by insulin action per se. We demon-
strated that the effects of etomoxir (in vivo and in vitro)
are mediated, in part, by LXR signaling (Figs. 4, 6, and 7).
The GLUT4 promoter regulatory region contains an LXRE
site, which we have now conﬁrmed binds to the LXR-
ligand both in adipose tissue, and 3T3-L1 adipocytes (Figs.
6 and 7). Similar to insulin, LXR signaling promotes the
synthesis and storage of lipids (28). It is quite reasonable
that LXR signaling would support production of GLUT4
mRNA during times when lipid storage in adipose tissue is
required. Etomoxir treatment reduced LXR- association
with the GLUT4 promoter, consistent with the conclusion
that LXR plays a positive role in GLUT4 gene transcription
through the LXRE.
Replenishment of etomoxir-treated cells with either
palmitoyl L-carnitine, the product of CPT-1 enzyme, and
LXR agonist each restored GLUT4 expression to near-
normal levels, suggesting that mitochondrial import of
long-chain fatty acids may play in regulating LXR signaling
in the adipocyte. This effect of LXR activation was present
in cultured cells, suggesting that systemic factors are not
involved. Thus, a metabolite of palmitate oxidation may
generate the LXR ligand. Conversely, fatty acid oxidation
may indirectly produce a LXR ligand. In hepatic cells, LXR
may function as a glucose sensor by directly binding
glucose or glucose-6-phosphate to induced LXR-dependent
transcriptional activation (45). Finally, inhibition of fatty
acid oxidation may lead to increased AMPK activation in
adipose tissue, as is observed in fasted adipocytes (46),
which in turn leads to decreased glucose uptake, lipogen-
esis, and fatty acid oxidation (41). In hepatic tissue, AMPK
activation has been shown to suppress LXR-dependent
gene transcription presumably through alterations in li-
gand production. It is possible that this mechanism also
operates in adipose tissue (47). In fact, changes in LXR
signaling may be part of the transition between the fed and
fasted state in adipose tissue and show that LXR is
responding to glucose ﬂux in adipose tissue. LXR signaling
may play a role in the adaptation to the metabolic stress
that accompanies over-nutrition and diabetes. For exam-
ple, treatment of obese insulin-resistant C57BL/6 mice
with an LXR agonist improved glucose homeostasis (48).
Future work is underway to determine the role of LXR
signaling to the GLUT4 promoter in states of relative
insulin deﬁciency.
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